Acorda Therapeutics Inc.
| NASDAQ: ACOR | Healthcare / Pharmaceuticals / USA |
| 11.60 | -0.9100 | -7.27% | Vol 6.77K | 1Y Perf 83.97% |
| Oct 4th, 2023 15:53 DELAYED |
| BID | 10.74 | ASK | 12.00 | ||
| Open | 12.70 | Previous Close | 12.51 | ||
| Pre-Market | - | After-Market | 15.96 | ||
| - - | 4.36 37.59% |
| Target Price | 10.00 | Analyst Rating | — 0.00 | |
| Potential % | -13.79 | Finscreener Ranking | ☆ 37.00 | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★ 41.97 | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ☆ 13.99 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 30.53 | Earnings Rating | Buy | |
| Market Cap | 14.41M | Earnings Date | 7th Nov 2023 | |
| Alpha | -0.04 | Standard Deviation | 0.42 | |
| Beta | 1.32 |
Today's Price Range 11.6012.70 | 52W Range 5.8024.80 | 5 Year PE Ratio Range -18.1024.70 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -14.14% | ||
| 1 Month | 2.12% | ||
| 3 Months | 0.48% | ||
| 6 Months | 12.58% | ||
| 1 Year | 83.97% | ||
| 3 Years | -81.39% | ||
| 5 Years | -99.44% | ||
| 10 Years | -99.71% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -22.88 | |||
ROE last 12 Months | -98.21 | |||
ROA (5Y Avg) | -18.90 | |||
ROA last 12 Months | -26.80 | |||
ROC (5Y Avg) | -13.77 | |||
ROC last 12 Months | -28.17 | |||
Return on invested Capital Q | -5.05 | |||
Return on invested Capital Y | -4.37 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 5.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.10 | ||||
| 0.25 | ||||
| 0.22 | ||||
| 7.40 | ||||
| -0.60 | ||||
| -1.61 | ||||
| 0.25 | ||||
| 3.11 | ||||
| 191.86M | ||||
| Forward PE | -15.61 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 1.70 | ||||
| 0.72 | ||||
| 2.56 | ||||
| -1.50 | ||||
| Leverage Ratio | 4.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 75.80 | ||||
| -37.00 | ||||
| -10.20 | ||||
| -91.60 | ||||
| -97.66 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 87.10M | ||||
| 3.58 | ||||
| -26.88 | ||||
| -28.47 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -7.55 | - |
| Q01 2023 | - | -0.69 | - |
| Q04 2022 | - | 0.57 | - |
| Q03 2022 | -0.10 | -0.57 | -470.00 |
| Q02 2022 | -0.36 | -2.78 | -672.22 |
| Q01 2022 | - | -1.93 | - |
| Q04 2021 | - | -1.73 | - |
| Q03 2021 | - | -2.43 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.15 | - | - |
| 12/2022 QR | -0.15 | 0.00 | - |
| 12/2022 FY | -0.96 | - | - |
| 12/2022 FY | -0.96 | 0.00 | - |
| Next Report Date | 7th Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 6.77K |
| Shares Outstanding | 1.24K |
| Shares Float | 1.22M |
| Trades Count | 168 |
| Dollar Volume | 83.95K |
| Avg. Volume | 7.15K |
| Avg. Weekly Volume | 4.97K |
| Avg. Monthly Volume | 7.95K |
| Avg. Quarterly Volume | 8.52K |
Acorda Therapeutics Inc. (NASDAQ: ACOR) stock closed at 12.51 per share at the end of the most recent trading day (a -11.4% change compared to the prior day closing price) with a volume of 12.73K shares and market capitalization of 14.41M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Pharmaceuticals industry, Healthcare sector and employs 130 people. Acorda Therapeutics Inc. CEO is Ron Cohen.
The one-year performance of Acorda Therapeutics Inc. stock is 83.97%, while year-to-date (YTD) performance is -18.42%. ACOR stock has a five-year performance of -99.44%. Its 52-week range is between 5.8 and 24.8, which gives ACOR stock a 52-week price range ratio of 30.53%
Acorda Therapeutics Inc. currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.25, a price-to-sale (PS) ratio of 0.22, a price to cashflow ratio of 7.40, a PEG ratio of -, a ROA of -26.80%, a ROC of -28.17% and a ROE of -98.21%. The company’s profit margin is -97.66%, its EBITDA margin is -10.20%, and its revenue ttm is $87.10 Million , which makes it $3.58 revenue per share.
Of the last four earnings reports from Acorda Therapeutics Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Acorda Therapeutics Inc.’s next earnings report date is 07th Nov 2023.
The consensus rating of Wall Street analysts for Acorda Therapeutics Inc. is — (0), with a target price of $10, which is -13.79% compared to the current price. The earnings rating for Acorda Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Acorda Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Acorda Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.53, ATR14 : 1.10, CCI20 : -111.52, Chaikin Money Flow : -0.10, MACD : -0.12, Money Flow Index : 31.52, ROC : -18.50, RSI : 36.66, STOCH (14,3) : 2.75, STOCH RSI : 0.00, UO : 35.51, Williams %R : -97.25), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Acorda Therapeutics Inc. in the last 12-months were: Cohen Ron (Buy at a value of $12 594), Ron Cohen (Buy at a value of $12 594)
Acorda Therapeutics Inc.
Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.
CEO: Ron Cohen
Telephone: +1 914 347-4300
Address: 420 Saw Mill River Road, Ardsley 10502, NY, US
Number of employees: 130
